Non-members: Click here to review a complimentary excerpt from “Best Practices in Scientific Publications Strategy: Neutral/Negative Results and Publication Best Practices”
Global scientific publications function at bio-pharmaceutical companies face increasing calls for improved transparency and data disclosure. Consequently, global publications leaders find themselves in a balancing act - ensuring both scientific credibility and commercial feasibility.
Best Practices, LLC undertook benchmarking research to explore how leading bio-pharmaceutical companies shape their global scientific publication strategies and plans to maintain credibility in the scientific community and drive commercial success. In particular, this study identifies publication strategy changes for the new marketplace, best practices for maximizing the effectiveness of strategic publication planning, top publication challenges and lessons learned for implementing successful scientific publication strategy.
- Tactics for Handling Publication of Neutral or Negative Clinical Trial Results
- Future Publishing Emphasis
- Strategy Changes for the New Marketplace
- Best Practices for Maximizing the Effectiveness of Strategic Publication Planning
- Top Publication Challenges
- Lessons Learned for Implementing Successful Scientific Publication Strategy
- Use of Scenario Planning for Publishing Neutral/Negative Clinical Trial Results
- How Will Journal Emphasis Change over Next Three Years to Provide Greater Transparency
- Changes Made to Maintain Publication Excellence
- Best Practices for Maximizing the Effectiveness of Medical / Scientific Strategic Publication Planning
- Top Medical Publication Challenges over the Next 1-3 Years
- Most Important Lessons Learned for Implementing Successful Scientific Publication Strategy
SAMPLE KEY FINDINGS
- Companies Use Scenario Planning for Publishing Neutral/Negative Clinical Trial Results: Two-thirds of companies use scenario planning as part of their strategy for publishing neutral and/or negative results. When building these scenarios, publication groups consider the content to be published, the timing for publication and the channel used for publication. Participants – and the industry in general - publish all data irrespective of the results within 1-1.5 years; however, the journal criteria is changed and lower-impact journals are used for publication.
Best Practices, LLC engaged 20 leaders from 19 leading bio-pharmaceutical companies with direct experience working in scientific publishing. Almost 75% of participants are from the U.S. region.